

CLAIMS

1. A therapeutic product for therapy of hemophilia comprising
hollow nano particles formed of protein exhibiting a particle forming
capability; and
genes for therapy of hemophilia embedded in said hollow nano particles.
2. A therapeutic product for therapy of hemophilia comprising
hollow nano particles formed by introducing bio-recognition molecules into
protein particles obtained on expressing the protein in eucaryotic cells; and
genes for therapy of hemophilia embedded in said hollow nano particles.
3. The therapeutic product for therapy of hemophilia according to claim 2
wherein
said eucaryotic cells are yeast or recombinant yeast.
4. The therapeutic product for therapy of hemophilia according to claim 2
wherein
said eucaryotic cells are insect cells.
5. The therapeutic product for therapy of hemophilia according to claim 2
wherein
said eucaryotic cells are animal cells.
6. The therapeutic product for therapy of hemophilia according to any one of
claims 1 to 5 wherein
said protein exhibiting the particle forming capability is hepatitis B virus

surface antigen protein.

7. The therapeutic product for therapy of hemophilia according to any one of claims 1 to 6 wherein

said gene for therapy of hemophilia is the clotting factor VIII or IX.

8. The therapeutic product for therapy of hemophilia according to any one of claims 1 to 7 wherein

the therapeutic product is administered to a human body by intravenous injection.

9. A method for therapy of hemophilia comprising administering the therapeutic product according to any one of claims 1 to 8.